Automated next-generation profiling of genomic alterations in human cancers.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
20 05 2022
Historique:
received: 26 01 2021
accepted: 27 04 2022
entrez: 20 5 2022
pubmed: 21 5 2022
medline: 25 5 2022
Statut: epublish

Résumé

The lack of validated, distributed comprehensive genomic profiling assays for patients with cancer inhibits access to precision oncology treatment. To address this, we describe elio tissue complete, which has been FDA-cleared for examination of 505 cancer-related genes. Independent analyses of clinically and biologically relevant sequence changes across 170 clinical tumor samples using MSK-IMPACT, FoundationOne, and PCR-based methods reveals a positive percent agreement of >97%. We observe high concordance with whole-exome sequencing for evaluation of tumor mutational burden for 307 solid tumors (Pearson r = 0.95) and comparison of the elio tissue complete microsatellite instability detection approach with an independent PCR assay for 223 samples displays a positive percent agreement of 99%. Finally, evaluation of amplifications and translocations against DNA- and RNA-based approaches exhibits >98% negative percent agreement and positive percent agreement of 86% and 82%, respectively. These methods provide an approach for pan-solid tumor comprehensive genomic profiling with high analytical performance.

Identifiants

pubmed: 35595835
doi: 10.1038/s41467-022-30380-x
pii: 10.1038/s41467-022-30380-x
pmc: PMC9123004
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2830

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014236
Pays : United States

Informations de copyright

© 2022. The Author(s).

Références

Nat Biotechnol. 2013 Nov;31(11):1023-31
pubmed: 24142049
Transl Lung Cancer Res. 2018 Dec;7(6):631-638
pubmed: 30505707
Transl Lung Cancer Res. 2018 Dec;7(6):661-667
pubmed: 30505710
J Hematol Oncol. 2019 May 31;12(1):54
pubmed: 31151482
Int J Cancer. 2019 Feb 15;144(4):848-858
pubmed: 30238975
Sci Transl Med. 2015 Apr 15;7(283):283ra53
pubmed: 25877891
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Cancer Discov. 2012 Jan;2(1):82-93
pubmed: 22585170
Ann Oncol. 2019 Jan 1;30(1):44-56
pubmed: 30395155
Nat Methods. 2018 Aug;15(8):591-594
pubmed: 30013048
Clin Lung Cancer. 2017 Nov;18(6):651-659
pubmed: 28479369
Nat Commun. 2017 Nov 9;8(1):1377
pubmed: 29123093
J Mol Diagn. 2015 May;17(3):251-64
pubmed: 25801821
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
N Engl J Med. 2014 Dec 25;371(26):2477-87
pubmed: 25426838
Cell Syst. 2018 Mar 28;6(3):271-281.e7
pubmed: 29596782
Sci Transl Med. 2018 Sep 5;10(457):
pubmed: 30185652
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Clin Pharmacol Ther. 2010 May;87(5):543-52
pubmed: 20237469
Front Oncol. 2018 Dec 12;8:621
pubmed: 30631754
Cell. 2018 Apr 5;173(2):371-385.e18
pubmed: 29625053
Am Soc Clin Oncol Educ Book. 2019 Jan;39:531-542
pubmed: 31099633
J Mol Diagn. 2021 Oct;23(10):1324-1333
pubmed: 34314880
Scientifica (Cairo). 2012;2012:917540
pubmed: 24278755
JCO Precis Oncol. 2017;2017:
pubmed: 29850653
J Clin Oncol. 2008 Apr 1;26(10):1626-34
pubmed: 18316791
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Appl Transl Genom. 2016 May 25;10:19-24
pubmed: 27668172
Nat Med. 2014 Jun;20(6):682-8
pubmed: 24836576
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Clin Cancer Res. 2019 Dec 1;25(23):7024-7034
pubmed: 31506389
Transl Lung Cancer Res. 2018 Dec;7(6):703-715
pubmed: 30505715
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
Dis Markers. 2004;20(4-5):251-7
pubmed: 15528790
PLoS One. 2015 Aug 07;10(8):e0132727
pubmed: 26252492
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
Science. 2018 Oct 12;362(6411):
pubmed: 30309915
Sci Transl Med. 2011 Nov 30;3(111):111ra121
pubmed: 22133722
Genome Med. 2016 Jul 26;8(1):79
pubmed: 27460824
Nat Commun. 2022 May 20;13(1):2830
pubmed: 35595835
Sci Transl Med. 2012 Nov 28;4(162):162ra154
pubmed: 23197571
Genome Res. 1999 Aug;9(8):677-9
pubmed: 10447503
Cancer Discov. 2012 Mar;2(3):214-26
pubmed: 22585993
Nat Cancer. 2020 Jan;1(1):99-111
pubmed: 32984843
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Nat Med. 2016 Nov;22(11):1342-1350
pubmed: 27694933

Auteurs

Laurel A Keefer (LA)

Personal Genome Diagnostics Inc., Baltimore, MD, 21224, USA.

James R White (JR)

Personal Genome Diagnostics Inc., Baltimore, MD, 21224, USA.

Derrick E Wood (DE)

Personal Genome Diagnostics Inc., Baltimore, MD, 21224, USA.

Kelly M R Gerding (KMR)

Personal Genome Diagnostics Inc., Baltimore, MD, 21224, USA.

Kenneth C Valkenburg (KC)

Personal Genome Diagnostics Inc., Baltimore, MD, 21224, USA.

David Riley (D)

Personal Genome Diagnostics Inc., Baltimore, MD, 21224, USA.

Christopher Gault (C)

Personal Genome Diagnostics Inc., Baltimore, MD, 21224, USA.

Eniko Papp (E)

Personal Genome Diagnostics Inc., Baltimore, MD, 21224, USA.

Christine M Vollmer (CM)

Personal Genome Diagnostics Inc., Baltimore, MD, 21224, USA.

Amy Greer (A)

Personal Genome Diagnostics Inc., Baltimore, MD, 21224, USA.

James Hernandez (J)

Personal Genome Diagnostics Inc., Baltimore, MD, 21224, USA.

Paul M McGregor (PM)

Personal Genome Diagnostics Inc., Baltimore, MD, 21224, USA.

Adriana Zingone (A)

Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20850, USA.

Bríd M Ryan (BM)

Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20850, USA.

Kristen Deak (K)

Department of Pathology, Duke University School of Medicine, Durham, NC, 27710, USA.

Shannon J McCall (SJ)

Department of Pathology, Duke University School of Medicine, Durham, NC, 27710, USA.

Michael B Datto (MB)

Department of Pathology, Duke University School of Medicine, Durham, NC, 27710, USA.

James L Prescott (JL)

PathGroup, Nashville, TN, 37217, USA.

John F Thompson (JF)

Personal Genome Diagnostics Inc., Baltimore, MD, 21224, USA.

Gustavo C Cerqueira (GC)

Personal Genome Diagnostics Inc., Baltimore, MD, 21224, USA.

Siân Jones (S)

Personal Genome Diagnostics Inc., Baltimore, MD, 21224, USA.

John K Simmons (JK)

Personal Genome Diagnostics Inc., Baltimore, MD, 21224, USA.

Abigail McElhinny (A)

Personal Genome Diagnostics Inc., Baltimore, MD, 21224, USA.

Jennifer Dickey (J)

Personal Genome Diagnostics Inc., Baltimore, MD, 21224, USA.

Samuel V Angiuoli (SV)

Personal Genome Diagnostics Inc., Baltimore, MD, 21224, USA.

Luis A Diaz (LA)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.

Victor E Velculescu (VE)

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.

Mark Sausen (M)

Personal Genome Diagnostics Inc., Baltimore, MD, 21224, USA. msausen@pgdx.com.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH